GlassScriptPhysician profile
Payal Patel
NPI 1801414917
$1,612.25
in general payments reported to CMS, 2019-2025
24 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $80.97 · 2024: $962 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.32 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $375.88 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $333.02 | 2024-2025 | |
| Pfizer INC. | $171.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.97 | 2022 | |
| Radius Health, INC. | $74.26 | 2024 | Tymlos |
| Amgen INC. | $72.82 | 2024 | Enbrel, Otezla, Krystexxa |
| Depuy Synthes Sales INC. | $47.93 | 2024 | Monovisc, Orthovisc |
| Otsuka America Pharmaceutical, INC. | $43.04 | 2021 | |
| Lilly USA, LLC | $42.57 | 2021 | |
| Merck Sharp & Dohme LLC | $42.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.96 | 2021 | |
| Dompe US, INC. | $33.67 | 2024-2025 | Oxervate |
| Ucb, INC. | $31.15 | 2024 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $29.44 | 2021 | |
| Paratek Pharmaceuticals, INC. | $28.66 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $25.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.35 | 2021 | |
| Bioventus LLC | $18.61 | 2025 | Gelsyn-3 |
| Novartis Pharmaceuticals Corporation | $18.46 | 2024 | |
| Novo Nordisk INC | $17.45 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.69 | 2024 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $15.18 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.